Forbes Daily: The Cannabis Industry’s High Hopes For Federal Reform
Cannabis federal reform is poised to transform clinical practice by standardizing product quality and expanding patient access across states. This reform could enable physicians to prescribe cannabis therapeutics rather than merely recommend them. The…
Meet The Cannabis Industry’s Trump Whisperer – Forbes Insight
This article highlights cannabis industry Trump policy influence affecting federal regulation and patient access. Understanding these political relationships is crucial for clinicians. Cannabis industry Trump policy influence impacts clinical practice…
Trump Advisor Highlights Delay in Cannabis Rescheduling (Newsletter: April 10, 2026)
The 2026 cannabis rescheduling news reveals delays in federal policy updates. A Trump advisor indicates administrative obstacles are holding up progress. This impacts clinical practice and patient access nationwide.
Cannabis Rescheduling Testimony in Congress (Newsletter: April 7, 2026)
The cannabis rescheduling testimony in Congress is a pivotal moment for federal cannabis policy. This testimony influences clinical practice by addressing regulatory barriers and prescribing pathways. Healthcare providers should monitor these…
Hawaii Senators Advocate for Federal Cannabis Legalization and Expungement
Federal cannabis legalization is gaining momentum as Hawaii senators advocate for reform. This change would improve healthcare access and enable interstate research collaboration. The push for federal cannabis legalization also includes clearing past…
A Look Inside The White House’s First Cannabis Products Enforcement Policy Meeting
The White House cannabis enforcement policy meeting marks a key step in federal coordination on cannabis regulation. This meeting impacts patient access and physician guidance on cannabis therapeutics. Monitoring these developments is essential for…
CMS Expands Patient Access with New Cannabis Policy Initiatives
CMS patient access cannabis policy is evolving with new initiatives aimed at expanding Medicare coverage. These changes signal a shift in federal healthcare regulations affecting patient-centered innovation. Clinicians should monitor these developments…
White House Schedules Cannabis Enforcement Meeting (Newsletter: March 27, 2026)
The federal cannabis enforcement policy is under review following the White House's scheduled meeting in March 2026. This policy directly affects patient access to medical cannabis and clinical practice guidelines. Healthcare providers should stay…
US Congressman Presses DOJ, DEA Heads on Cannabis Rescheduling Timeline
The cannabis rescheduling timeline is critical for advancing federal regulation and medical cannabis research. Congressional pressure on DOJ and DEA heads highlights the urgency of this policy shift. This change could remove barriers to clinical trials…
Medicare’s Cannabis (CBD) Coverage Plan Sparks Federal Controversy
Medicare CBD policy access is a critical issue affecting patient care and clinical practice. Federal controversy surrounds cannabis coverage decisions by CMS. This debate impacts access for millions relying on Medicare.